LaunchTrends®: Xofigo is a series of three post-launch syndicated reports designed to track physician perception, uptake, and the competitive environment of newly launched Xofigo (Algeta/Bayer…
In an Increasingly Generic Market, Replete with Well-Established Oral Therapies, What Drug Development Opportunities Remain? In 2012, painful diabetic neuropathy (PDN) affected more than 7.4…
In an Increasingly Generic Market, Replete with Well-Established Oral Therapies, What Drug Development Opportunities Remain? In 2012, painful diabetic neuropathy (PDN) affected more than 7.4…
Last Updated 13 December 2013 The prostate cancer market has witnessed considerable changes over the last three years, owing to the launch of five new therapies for treatment of metastatic castrate…
Last Updated 9 December 2013 The sizable therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand. More patients…
Methicillin-resistant Staphylococcus aureus (MRSA) is an important causative pathogen of a range of hospital-treated infections. The steadily increasing severity of infections caused by MRSA that…